An interventional study of Midurethral sling placed before robotic sacrocolpopexy and Midurethral sling placed after robotic sacrocolpopexy in Stress Incontinence Female and Pelvic Organ Prolapse, sponsored by University of Alabama at Birmingham. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 195 studies in Pelvic Organ Prolapse with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Pelvic Organ Prolapse · United States.
Among the 195 studies in Pelvic Organ Prolapse with a site in United States, this one is the 46th largest by planned enrollment of the 133 interventional ones that give a count, is one of 6 that started in 2025, is one of 90 with no phase, reaches primary completion later than 13 of the 22 other live ones, and was the 186th registered.
522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.
Browse Pelvic Organ Prolapse studies →12 of the 195 studies in Pelvic Organ Prolapse with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+ · Women only
Cassandra Kisby · Sites in United States
Ages 21+ · Women only
The Cleveland Clinic · Sites in United States
Ages 18+
NICHD Pelvic Floor Disorders Network · Sites in United States
Ages 18–99 · Women only
University of Texas at Austin · Sites in United States
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 9 · Phase 4 25
First in 1996; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 80 across 337 interventional studies indexed under Pelvic Organ Prolapse.
Median enrollment 78 across the 133 interventional studies, 103 across the 61 observational. Of the 154 that completed or were terminated, 51 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 195 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 4 studies filed under Pelvic Organ Prolapse — fewer than ten, so there is no comparison to draw.
8 of the studies in Pelvic Organ Prolapse with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04179955Mayo ClinicIntraoperative Costs and Patient Perceptions in Sacrocolpopexy for Prolapse | 2026-12 |
| NCT06634459Medstar Health Research InstitutePOMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment | 2027-01 |
| NCT07008898University of Alabama at BirminghamSequence of Midurethral Sling Placement During Robotic Sacrocolpopexy | 2027-05 |
| NCT07692789Ohio State UniversityImproving Uroflowmetry Interpretability: Evaluating the Impact of Patient Reminder Systems | 2027-06 |
| NCT07218016NICHD Pelvic Floor Disorders NetworkAccelerometer Measured Early Recovery After Prolapse Surgery | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 195 studies in Pelvic Organ Prolapse with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study looks at the best time to place a midurethral sling (MUS), which is a small piece of mesh used to treat stress urinary incontinence (SUI) (leaking urine when you cough, laugh, or exercise). The sling is placed during a type of surgery called robotic sacrocolpopexy (RSC). This surgery helps fix pelvic organ prolapse, when organs like the bladder or uterus drop from their normal place.
Doctors can place the sling either before or after they lift and support the top of the vagina during surgery, but they aren't sure which timing works better. In this study, investigators are comparing what is the best time to place the sling, how the patient feels after surgery and if a patient's symptoms got better or worse.
Investigators will conduct a prospective, randomized, noninferiority trial on patients undergoing retropubic midurethral sling (RP MUS) placement at the time of robotic-assisted sacrocolpopexy (RSC).
Patients scheduled to undergo retropubic midurethral sling placement at the time of robotic- assisted sacrocolpopexy will be invited to participate during regularly scheduled preoperative visits with their urogynecologic provider. Participants will be randomized to receive RP MUS before RSC or after RSC. Randomization will be conducted in RedCap. Randomization will be performed using a variable permutated block randomization scheme. The Randomization window will be +/- 4 days before their scheduled surgery, and patients will be blinded to sequence of MUS placement intraoperatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Able to speak and read English and Spanish
Exclusion Criteria:
Midurethral sling placed after robotic sacrocolpopexy
Procedure: Midurethral sling placed before robotic sacrocolpopexy
Procedure: Midurethral sling placed after robotic sacrocolpopexy
Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.
Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.
Urinary Distress Index, Short Form (UDI-6) scores at 3 months postoperative
The primary outcome will be change between baseline and 3 months stress urinary incontinence symptoms as measured by the UDI-6. Scores for the UDI-6 range from 0 to 100 has an MCID of 5.8, with higher scores indicating worse symptoms.
Time frame: 3 months
Provocative stress test results at 6 weeks postoperative
Patients will be examined in the office during 6-week postoperative visit as is routine practice and assess for leakage of urine during empty supine provocative cough stress test.
Time frame: 6 weeks
Need for re-treatment for stress urinary incontinence (SUI) at 6 weeks postoperative
If recurrent stress urinary incontinence is noted to be present at 6-weeks postoperative, whether or not patients elect to proceed with additional treatment will be assessed.
Time frame: 6 weeks
Change in total Pelvic Organ Prolapse/Incontinence Sexual Questionnaire (PISQ-IR) at 3 months postoperative
PISQ-IR will be administered at enrollment and at 3 months postoperative, and scores will be compared.
Time frame: 3 months
Change in total Incontinence Impact Questionnaire, Short Form (IIQ-7) scores at 3 months postoperative
IIQ-7 will be administered to patients at enrollment and at 3 months postoperative, and scores at these two time points will be compared.
Time frame: 3 months
Complications (graded as Clavien Dindo)
Complications occurring during or after concomitant RSC and RP MUS will be recorded between both groups and compared.
Time frame: 6 weeks
Objective surgical data such as operative time
Objective surgical data such as operative time will be recorded between both groups and compared.
Time frame: 6 weeks
Objective surgical data such as estimated blood loss (EBL)
Objective surgical data such as estimated blood loss (EBL) will be recorded between both groups and compared.
Time frame: 6 weeks
Patient satisfaction (a decision scale and decision regret scale)
A decision regret scale will be administered to patients at 3 months postoperative, and scores will be compared between the two groups to assess if any difference in patient satisfaction exists.
Time frame: 3 months
Patient satisfaction (Patient Global Impression of Improvement (PGI-I) for Incontinence)
The PGI-I will be administered to all patients at 3 months to assess patient satisfaction with the procedure performed; any differences between groups in patient satisfaction will be assessed with this outcome.
Time frame: 3 months
Plan to share: Yes — Minimum necessay IPD will be shared with other researchers if trial is expanded to multiple sites.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.
Of 162 non-industry interventional studies with no phase under Pelvic Organ Prolapse, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 22 months is close to that.
Counting every sponsor, half of 179 studies reached it within 23 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →